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ABSTRACT During dermal wound healing, platelet-derived growth factor (PDGF) serves as both a chemoattractant and
mitogen for ﬁbroblasts, potently stimulating their invasion of the ﬁbrin clot over a period of several days. A mathematical model
of this process is presented, which accurately accounts for the sensitivity of PDGF gradient sensing through PDGF receptor/
phosphoinositide 3-kinase-mediated signal transduction. Analysis of the model suggests that PDGF receptor-mediated
endocytosis and degradation of PDGF allows a constant PDGF concentration proﬁle to be maintained at the leading front of the
ﬁbroblast density proﬁle as it propagates, at a constant rate, into the clot. Thus, the constant PDGF gradient can span the
optimal concentration range for asymmetric phosphoinositide 3-kinase signaling and ﬁbroblast chemotaxis, with near-maximal
invasion rates elicited over a relatively broad range of PDGF secretion rates. A somewhat surprising ﬁnding was that extremely
sharp PDGF gradients do not necessarily stimulate faster progression through the clot, because maintaining such a gradient
through PDGF consumption is a potentially rate-limiting process.
INTRODUCTION
Wound healing requires the concerted efforts of multiple cell
types (1,2). Of these cells, dermal ﬁbroblasts are responsible
for reproducing, remodeling, and later contracting the
extracellular matrix (ECM) to rebuild and condense the
regenerated tissue, but ﬁrst they must invade the provisional
matrix of the ﬁbrin clot. The ﬁbroblast response, through a
combination of directed migration (taxis) and proliferation,
develops over several days thereafter, forming ﬁbroblast-
dense granulation tissue that gradually penetrates the clot.
The progression of wound invasion and closure is controlled
by soluble factors released in the clot and by the ECM, and
overactive cell proliferation and matrix deposition results in
pathologically abnormal healing, or ﬁbrosis (3,4). Fibroblast
invasion, as a rate-limiting process in wound healing, is thus
a critical factor in the efﬁciency and ﬁdelity of tissue repair.
The ﬁrst step in the wound-healing cascade is the ag-
gregation and activation of blood platelets, which release
platelet-derived growth factor (PDGF) in the clot. PDGF acts
as a potent chemoattractant for ﬁbroblasts (5–7) and also
stimulates their proliferation, thus increasing the density of
ﬁbroblasts as they migrate into the ﬁbrin clot. Other
important stimuli released by platelets include transforming
growth factor b, which eventually stimulates ﬁbroblasts to
produce collagen and ﬁbronectin ECM, and insulin-like
growth factor-1, which enhances ﬁbroblast proliferation (8–
12). Another early event, typically elicited in the ﬁrst 24 h
postwounding (13), is the recruitment and activation of
neutrophils and macrophages, mediators of innate immunity.
Activated macrophages secrete PDGF, transforming growth
factor b, and other growth factors, reinforcing or replacing
platelet-derived signals aimed at ﬁbroblasts. Although it is
clear that many factors inﬂuence ﬁbroblast responses, PDGF
is unique in its ability to accelerate ﬁbroblast invasion
(6,10,14).
How are ﬁbroblast responses elicited by PDGF transduced
inside the cell? PDGF receptors belong to the well-studied
receptor tyrosine kinase class of signal transducers; as with
other receptor tyrosine kinases, ligand-induced dimerization
of PDGF receptors activates their intrinsic kinase activity,
leading to receptor transphosphorylation on selected intra-
cellular tyrosine residues and recruitment of cytosolic sig-
naling proteins (15–17). Of particular importance in PDGF
signaling is the phosphoinositide (PI) 3-kinase pathway
(18,19), due to its particularly strong activation by the PDGF
receptor (20,21) and its roles in multiple functional responses
(22). PI 3-kinases catalyze phosphorylation of phosphati-
dylinositols, producing speciﬁc 39 PI lipid second messen-
gers in the plasmamembrane. This pathway leads to modulation
of the cytoskeleton, in a localized manner that is biased by
chemoattractant gradients, and is required for PDGF-stimulated
motility and chemotaxis (23–27).
We have recently characterized the kinetics, dose respon-
siveness, and spatial regulation of PDGF receptor-mediated
PI 3-kinase signaling, culminating in an experimentally
validated, mechanistic model of PDGF gradient sensing (28–32).
Compared with the chemotactic responses of the model cell
systems, Dictyostelium discoideum and neutrophils, we
found that PDGF gradient sensing in ﬁbroblasts exhibits
less sensitivity in general and a greater dependence on the
midpoint concentration of the gradient. Optimal gradient
sensing is observed in a relatively narrow range of PDGF
concentrations that yield near maximal PI 3-kinase recruit-
ment without saturating PDGF receptor occupancy. From the
standpoint of wound healing, this insight at the single-cell
level has led us to question how a suitable gradient might be
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maintained throughout the clot as the ﬁbroblast population
invades, a question I aim to address here through analysis of
an invasion model focused on PDGF-stimulated responses.
Spatially directed cell migration and wound invasion have
been described and analyzed extensively using mathematical
models. Migration of a cell population in a chemoattractant
ﬁeld has long been treated as a macroscopic transport process,
with cell dispersion and chemotaxis modeled by analogy to
molecular diffusion and convective mass transfer, respectively
(33–36). Another important modiﬁcation was the recognition
that chemoattraction is receptor-mediated and thus saturable,
which lent some molecular/mechanistic basis to the modeling
of eukaryotic cell movement ((37), and references therein);
however, even recently this important aspect has not been
adopted in most models. Elegant, phenomenological models
focusing speciﬁcally on cellular dynamics during wound
healing have described ECM and growth factor effects on
ﬁbroblast migration, proliferation, and/or collagen production,
and have illustrated the importance of ﬁbroblast taxis in the
invasion process (38–44). None of these models faithfully
accounts for receptor dynamics and intracellular processes,
however, to include ligand binding as well as receptor acti-
vation, regulation, and signaling, and in most cases it is neither
practical nor prudent to do so. With our recent analyses, we
may now connect the dots between the PDGF concentration
proﬁle and PI 3-kinase-mediated ﬁbroblast migration signaling.
Incorporating an accurate description of PDGF gradient
sensing in a simpliﬁed model of wound invasion, I show that
a constant PDGF gradient and chemotactic signaling can be
maintained at the leading front of the ﬁbroblast population
through induced, receptor-mediated endocytosis and con-
sumption of PDGF. This effect is directly coupled to the
level of receptor activation and thus intracellular signaling to
proliferation and migration responses, forming an integrated
control mechanism for chemotaxis in tissues.
MODEL FORMULATION
Single-cell level: coarse-grained model
of PI 3-kinase signaling
Cell migration is assumed here to depend on PI 3-kinase signaling, which we
have quantitatively characterized. In developing the model at the intracel-
lular level (Fig. 1 a), all variables are deﬁned as dimensionless quantities.
Across the characteristic length of a cell, deﬁned as e, the PDGF gradient is
assumed to be nearly constant, giving the local ligand concentration u at any
relative cellular position j (0 # j # 1, with j ¼ 0 and j ¼ 1 deﬁning the
trailing and leading edges, respectively):
uðjÞ ¼ u1 ðj  1=2Þeð=uÞ: (1)
For gradients inmore thanone spatial dimension,u(j) is treated as a vectorwith
orthogonal components. Note that, in this article, averaging over cell
orientations relative to the gradient is implicit. The local receptor activation
at quasi-steady state, r, is related to the local ligand concentration by the
expression,
rðuÞ ¼ u
2
11 u1 u2
; (2)
which accurately reﬂects the degree of cooperativity observed in the dose
response of PDGF receptor phosphorylation (28). The quasi-steady-state
approximation is appropriate given the separation of timescales between the
receptor- and cell population-level dynamics (minutes versus hours).
Although the phenomenological form of Eq. 2 was offered previously
(32), it is shown in Appendix A to be a more than adequate approximation of
a mechanistic model incorporating receptor binding, dimerization, and
trafﬁcking. From Eq. 2, the average receptor activation in the cell is obtained
by integration, with the suitable approximation
Æræ  rðuÞ: (3)
Equation 3 is derived in Appendix B.
FIGURE 1 Model schematic. (a) Single-cell model. The dimensionless
PDGF concentration u controls activation of cell surface receptors locally;
activated receptors bind the PI 3-kinase enzyme, drawing upon a homoge-
neous cytosolic pool, yielding a local increase in the density of 39 PI lipid
messengers in the plasma membrane. Randommigration and chemotaxis are
assumed to depend on the average 39 PI density and the asymmetry in the 39
PI proﬁle, respectively, and are coupled in a consistent way to ﬁbroblast
proliferation and receptor-mediated PDGF clearance. (b) Macroscopic
model. The PDGF concentration u and ﬁbroblast density v evolve as a
function of time and location in two tissue domains: a ﬁnite clot, where
PDGF is produced by platelets and macrophages (normalized rate ks), and an
adjoining, semi-inﬁnite dermis, where the ﬁbroblasts are initially found at a
constant, resting density (v ¼ 1). A one-dimensional patch wound with clot
thickness l is depicted here.
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Cell motility signaling is mediated by an intracellular second messenger,
m (39 PIs), produced by an activated enzyme, e (PI 3-kinase), which is
activated by receptor-mediated binding at the plasmamembrane. Both are expres-
sed as scaled variables. The equations governing enzyme activation are as
derived previously (32). The fractional enzyme activation, e, is assumed to be at
all locations in pseudo-equilibrium with a common pool of cytosolic enzyme
molecules, with relatively fast enzyme diffusion in the cytosol:
eðjÞ ¼ arðjÞð1 ÆeæÞ
k1 1 Æeæ : (4)
The two constant parameters here are the receptor/PI 3-kinase expression ratio,
a, and normalized dissociation constant, k. The average enzyme binding, Æeæ,
also satisﬁes the equilibrium relationship, allowing one to solve for it:
Æeæ ¼ aÆræð1 ÆeæÞ
k1 1 Æeæ : (5)
The steady-state messenger density proﬁle, m(j), is subject to production by
locally activated and cytosolic PI 3-kinase and consumption characterized
by a ﬁrst-order rate constant (28,30). It is scaled such that its average value,
Æmæ, is 1 when Æeæ ¼ 1; in the absence of stimulation, with all PI 3-kinase in
the cytosol (e ¼ 0), the basal value of m is deﬁned as m0. Hence, the balance
on m is given by
mðjÞ ¼ eðjÞ1m0ð1 ÆeæÞ: (6)
The potential blurring of the messenger gradient via its lateral diffusion in
the cell membrane is not considered here, although a suitable approximation
of this effect may be incorporated readily (results not shown).
Cell population level: phenomenological model
of ﬁbroblast invasion
The following equations apply to the wounded region, which includes both
the ﬁbrin clot and the neighboring dermis (Fig. 1 b). It is assumed that
conditions are such that there is a natural separation of timescales between
platelet and macrophage activation and the ﬁbroblast invasion process
described by the model, and between invasion and the ultimate contraction
and resolution of the wound. At the tissue level, cells at a given location
experience an average PDGF concentration u; in light of the approximation
in Eq. 3, the distinctions between u and u, and between r and Æræ, are dropped
from this point forward. The dimensionless ﬁbroblast density, v, is scaled
such that v ¼ 1 in the dermis initially. PDGF is secreted only in the clot, at a
constant, normalized rate ks (in general, ks could depend on time and location
in the wound), and the ligand is degraded spontaneously and through
receptor-mediated endocytosis by ﬁbroblasts:
@u
@t
¼ Du=2u1 ks  kuu kvrv: (7)
Cells proliferate at a normalized net rate Rp, and they invade the clot through
random migration (dispersion coefﬁcient Dv) and chemotaxis:
@v
@t
¼ =  Jv1Rp;
 Jv ¼ Dv=v1 Stax  Dv
S
=S
 
v: (8)
The general form of the cell migration ﬂux vector, Jv, which includes the
variation of random migration speed with chemoattractant concentration
(chemokinesis), is from the derivation by Alt (34). S is the average cell
migration speed, and the chemotactic ﬂux is given by Staxv, where the che-
motactic cell speed Stax depends on the extracellular PDGF gradient
experienced by cells at that location (see below). Note that when higher
chemoattractant concentrations yield faster random migration, chemokinesis
and chemotaxis are in opposition with respect to migration in the direction of
the chemoattractant gradient.
Although cell migration signaling is the focus of this model, ﬁbroblast
proliferation and survival are arguably just as important in the ﬁbroblast
invasion process. An appropriate phenomenological expression is assumed
here, without regard to speciﬁc pathways for now:
Rp ¼ mmr
g1 r
 
1 v
v

 nh i
v kdðv v0Þ: (9)
The parameters g, v*, and kd account for saturability of proliferation
signaling, contact inhibition, and survival threshold, respectively. The
resting ﬁbroblast density, v0, is taken as 1 in the dermis and 0 in the clot.
The ﬁnal piece of the wound invasion model is to specify the relationship
between intracellular signaling and the ﬂux of the ﬁbroblast population
introduced in Eq. 8. Random migration and chemotaxis are coupled to the
average concentration and concentration gradient of the messenger inside
the cell, respectively (see also Appendix B); the difference in m between the
front and rear portions of the cell, Dm (technically, a vector), determines the
fraction of the cell speed that contributes to directed motion, akin to a tug-of-
war. Dimensionless quantities are thus deﬁned:
Dv
D

v
¼ S
S
 ¼ Æmæ ¼ Æeæ1bð1 ÆeæÞ;
Stax
Stax
¼ Dm ¼ 2
Z 1
1=2
mdj 
Z 1=2
0
mdj
 
:
(10)
Random and directed components of ﬁbroblast migration are thus related in
a consistent way to PDGF receptor-mediated PI 3-kinase activation. In that
regard, it is noteworthy that the same dependence was assigned for the
dispersion coefﬁcient Dv and overall cell speed S. Dv is proportional to S
2P,
where P is the persistence time, and so the ratio of Dv/S is proportional to the
average run length SP. Consistent with Eq. 10, experiments with ﬁbroblasts
in culture have shown that this quantity is insensitive to perturbations, at
least in certain situations; S and P are affected in a reciprocal manner (45).
Dv and S are related to Æmæ simply by proportionality constants; a more
complicated dependence could be imposed if warranted. With Eq. 10, the
migration ﬂux in Eq. 8 may now be written as
Jv ¼ DvÆmæ=v1 ðStaxDm Dv=ÆmæÞv: (11)
Model implementation
Deﬁnitions and base values of all model parameters are summarized in Table
1, and justiﬁcation for certain parameter values is offered in Appendix C.
Finite-element model calculations were performed using FEMLAB (COM-
SOL, Burlington, MA). Initial and boundary conditions were as follows (Fig.
1 b). In both the clot and dermis, u ¼ 0 initially. It was assumed that PDGF is
only produced in the clot, that cell quiescence is only supported in the dermis
(v(0)¼ v0¼ 1 in the dermis, 0 in the clot), and that there is no ﬂux of PDGF or
cells (=u ¼ Jv ¼ 0) normal to the top surface of the ‘‘skin’’. Concentrations
and ﬂuxes were matched across the clot-dermis interface. The dermis was
extended to a sufﬁcient size (well beyond what is plotted in the ﬁgures), with a
characteristic length scale several times greater than (Du/ku)
1/2, and therefore it
was speciﬁed that u ¼ 0, v ¼ 1 at the outer boundary of the dermis.
RESULTS
PDGF gradient sensing and ﬁbroblast
chemotaxis is optimized in a speciﬁc range
of PDGF concentrations
A key feature of the model, based on quantitative experiments
(28,30,32), is saturable activation of the PI 3-kinase enzyme
Model of PDGF-Mediated Wound Invasion 2299
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(Eqs. 4 and 5). This means that near-maximal enzyme
recruitment can be achieved with submaximal receptor
activation, requiring that a . 1 and a  k; order-of-
magnitude values of a ¼ 10, k ¼ 0.1 are consistent with the
dose responses of PDGF receptor and PI 3-kinase activation in
mouse ﬁbroblasts. Thus, there is an intermediate regime of
PDGF concentrations that yield near-maximal enzyme re-
cruitment and random ﬁbroblast migration (Æeæ, Æmæ,Dv=Dv 
1) yet also elicit the greatest contrast in signaling between the
front and rear of a cell in a PDGF gradient (Fig. 2 a). The
PDGF concentration that gives optimal gradient sensing and
chemotaxis, uopt, is insensitive to the relative steepness of the
gradient, deﬁned as d ¼ eu1j=uj ¼ ej=lnuj. For the values
of a and k chosen, uopt  0.5, and u ; 0.2–2 yield at least
half-maximal gradient sensing (Fig. 2 b). At much lower
PDGF concentrations, enzyme activation is low; at much higher
concentrations, enzyme activation is maximal, but receptor
saturation precludes gradient perception.
Reconciliation of ﬁbroblast proliferation and
ﬁbroblast-mediated PDGF consumption deﬁnes
the dynamic range of PDGF concentration
in the clot
The other pivotal feature of the model is the coupling
between receptor activation and cell density-dependent
PDGF consumption through receptor-mediated endocyto-
sis, which results in a trade-off between cell proliferation
and PDGF depletion. This trade-off is best assessed through
an analysis of steady-state nullclines associated with the
PDGF and ﬁbroblast conservation equations in the clot,
assuming no spatial gradients (Fig. 3). Equations 7–9 thus
reduce to
ks  kuu kvrv ¼ 0; (12)
mmr
g1 r
 "
1 v
v

 n#
v kdv ¼ 0: (13)
Equations 12 and 13 have a trivial solution, with v ¼ 0, u ¼
ks/ku¼ umax; Eq. 13 dictates that the cells can only proliferate
TABLE 1 Model parameters and order-of-magnitude,
base-case values
Parameter Deﬁnition Base value
ey Characteristic cell dimension 0.03 mm
a Maximum receptor/PI 3-kinase ratio 10
k Dimensionless KD, PI 3-kinase
recruitment
0.1
m0 Dimensionless 39 PI density,
unstimulated
0.1
ks Normalized PDGF secretion rate
in the clot
1 h1
Du PDGF diffusion coefﬁcient in tissue 0.01 mm
2/h*
ku Rate constant, spontaneous PDGF
degradation
0.1 h1
kv Rate constant, ﬁbroblast-mediated
PDGF depletion
1 h1*
mm Rate constant, maximal
ﬁbroblast growth
0.05 h1
g Dimensionless saturation constant,
ﬁbroblast growth
0.1
v* Dimensionless, contact-inhibited
ﬁbroblast density
10
n Contact inhibition sensitivity
parameter
3
kd Rate constant, ﬁbroblast death 0.01 h
1
v0 Dimensionless resting cell density,
clot (dermis)
1 (0)
Dv Maximum ﬁbroblast dispersion
coefﬁcient
3 3 104 mm2/h*
Staxy Maximum chemotactic cell speed 0.1 mm/h*
*The values of these parameters are discussed in Appendix C.
yThe product of these two parameters may be lumped as one in this model.
FIGURE 2 PDGF gradient sensing is optimized at intermediate PDGF
concentrations. Analysis of the single-cell model (Eqs. 2–6) is presented,
assuming a ¼ 10, k ¼ 0.1, m0 ¼ 0.1. (a) Average receptor activation and 39
PI messenger level, and messenger levels at the front (j ¼ 1) and back
(j ¼ 0) of the cell, for PDGF gradients of varying midpoint PDGF
concentration and a 30% gradient across the cell. (b) The difference between
front and rear messenger levels [m(1) – m(0) ¼ e(1) – e(0)] is plotted as a
function of midpoint PDGF concentration with relative gradient d ¼ 0.02,
0.05, 0.1, 0.2, 0.5, or 1. The curves peak at u ¼ uopt  0.5.
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when the PDGF concentration exceeds a critical value ucrit,
satisﬁed by rðucritÞ ¼ kdg= mm  kdð Þ, and it follows that the
trivial solution is only stable when umax#ucrit. When umax
exceeds ucrit, there exists an asymptotically stable nontrivial
solution (uy,vy), with vy. 0, uy, umax. One concludes that
the dynamic range of PDGF concentration in the clot, where
v ¼ 0 initially, is bounded by uy and umax. Hence, the PDGF
dynamic range is deﬁned as
Du ¼ umax  uy: (14)
Aspects of the proliferation term, Eq. 9, determine the
sensitivity of the solution (uy,vy) to the PDGF rate constants,
ks, ku, and kv. With a threshold receptor activation that must
be met for survival in the clot, and contact-inhibited growth
at high cell density, one ﬁnds regimes in which only one
of uy or vy is sensitive to these rate constants. When PDGF
is limiting for cell growth, the PDGF concentration is
maintained near its critical value, with uy ucrit. Conversely,
when PDGF production is in excess, the cell density is
maximal, with vy  vmax ¼ v½1 kd g11ð Þ=mm1=n. In
the intermediate or ‘‘cusp’’ regime, one ﬁnds that uy ; ucrit
and vy ; vmax (Fig. 3).
The analysis outlined here suggests how chemotaxis of the
invading ﬁbroblasts may be sensitive to PDGF concentration
yet robustly maintained throughout the clot. As long as uy;
uopt or less, and umax uopt, the ﬁbroblasts will experience a
suitable gradient for chemotaxis. Further, the sharpness of
the gradient will be maximized when Du is large and the cell
density is high; the aforementioned cusp region of PDGF
production best satisﬁes these criteria.
Fibroblast-mediated PDGF consumption allows
for the maintenance of a constant PDGF
gradient that propagates in tandem with
the invading ﬁbroblast front
Model calculations were performed for a ‘‘patch’’ wound,
with gradients in only one dimension, assuming a clot
thickness l ¼ 3 mm (Fig. 1 b; Fig. 4, a–d). At time t ¼ 0,
there is no PDGF in either the clot or dermis, and ﬁbroblasts
reside only in the dermis at a constant density v ¼ 1;
thereafter, PDGF is produced at a constant rate throughout
the clot, and ﬁbroblasts are allowed to move from the dermis
FIGURE 3 Dynamic range of the PDGF concentration proﬁle in the clot.
The steady-state nullclines, in the absence of spatial gradients, describe
conditionswhere PDGF synthesis and consumption are balanced (Eq. 12;dot-
dashed curve, base-case parameters; dotted curve, consumption byﬁbroblasts
only, with ku ¼ 0) or where there is zero net ﬁbroblast growth (Eq. 13, solid
curve). The intersection of these curves, (uy,vy), satisﬁes both criteria,
bounding the PDGF concentration proﬁle between uy and umax ¼ ks/ku.
FIGURE 4 Progression of wound invasion. (a–d) Model calculations
were performed assuming base-case parameters and a one-dimensional
patch clot with thickness l ¼ 3 mm. Proﬁles of PDGF concentration u ((a)
dashed line, u ¼ uy ¼ 0.424), ﬁbroblast density v ((b) dashed line: v ¼ vy¼
8.53), and chemotactic signaling Dm (c) at the indicated times in days are
shown. (d) The ﬁbroblast penetration depth, deﬁned here as the maximum
distance into the clot at which v ¼ 0.5, increases linearly with time after a
transient of ;2 days. (e) Model calculations assuming a two-dimensional
slash clot. The V-shaped clot has a depth of 10 mm and a width of 5 mm at
the top; the dimensions of the tissue portion shown are 203 20 mm. Proﬁles
of PDGF concentration (scale, 0–10), ﬁbroblast density (scale, 0–10), and
chemotactic signaling (scale, 0–0.1) are shown at t¼ 7 days. The magnitude
of the latter incorporates both x- and y-components of the Dm vector,
according to jDmj ¼ ½ Dmð Þ2x1 Dmð Þ2y1=2.
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into the clot. The calculated PDGF and ﬁbroblast density
proﬁles at various times, with base-case parameter values
(Table 1), are shown in Fig. 4, a and b. The PDGF con-
centration proﬁle that develops over several days shows that
deﬁning its dynamic range in terms of umax and u
y (Eq. 14) is
a good approximation (Fig. 4 a); for the base case, umax¼ 10,
corresponding to a low nanomolar PDGF concentration (see
Appendix C). The cell density proﬁle develops two maxima
for this set of parameter values, at the clot-dermis interface and
at the leading ﬁbroblast front (Fig. 4 b). These maxima
coincide spatially with sharp peaks in chemotactic signaling,
Dm, brought about by the contrasts in PDGF production (clot-
dermis) and ﬁbroblast density (leading front) (Fig. 4 c). After
;3 days, the shapes of the cell front and PDGF concentration
proﬁles remain roughly the same as they move through the
clot, and the penetration depth of the ﬁbroblast front (deﬁned
here as the maximum distance into the clot where v ¼ 0.5)
increases linearly with time (Fig. 4 d). These features of the
PDGF concentration and ﬁbroblast density proﬁles were
reproduced in a two-dimensional ‘‘slash’’ wound model (Fig.
4 e and Movie 1 in the Supplementary Material), with nearly
identical Dm peak values and ﬁbroblast penetration rate. In the
following sections, it is demonstrated that the Dm peak at the
leading front and the overall rate of ﬁbroblast invasion stem
from the PDGF dynamic range, Du, and its relation to uopt, as
analyzed in Figs. 2 and 3.
Fibroblast invasiveness is driven by chemotactic
signaling at the leading ﬁbroblast front and is
optimized across a reasonably broad range
of PDGF secretion rates
When the normalized rate of PDGF secretion, ks, is either too
low (vy  vmax or umax , uopt) or too high (uy  1), it is
reasoned that ﬁbroblast chemotaxis and thus the rate of
wound invasion should suffer. From a series of model
calculations, it was conﬁrmed that the ﬁbroblast penetration
depth at t ¼ 10 days is indeed reduced when the PDGF
secretion rate, ks, is increased or decreased signiﬁcantly (Fig.
5 a). Also shown on this plot is the total cell population size
in the clot (
R l
0
vdx), also at t ¼ 10 days, another indicator of
the quality of response. In the limit of very low ks, such that
umax , ucrit, there is a net cell death in the clot, and the
ﬁbroblast population cannot propagate into the wound. As ks
is increased above the critical value, there is a sharp increase
in penetration depth, corresponding with an increase in the
PDGF dynamic range, Du. At intermediate PDGF secretion
rates, the system is surprisingly robust, with an order-of-
magnitude span of ks values (0.2–2 h
1) that support ﬁbro-
blast invasion velocities .80% of the maximum. As the
secretion rate is increased even further, sufﬁcient for receptor
saturation (uy 1; r 1), ﬁbroblast invasiveness is reduced
to a plateau level. In that limit, it is noted that Eqs. 8–11
reduce to the generalized form of Fisher’s equation (46):
FIGURE 5 Sensitivity of ﬁbroblast invasiveness to
PDGF secretion rate. Calculations were performed as in
Fig. 4, a–d, after adjustments to the normalized PDGF
secretion rate, ks. The dimensionless saturation constant
for ﬁbroblast proliferation was set at the base-case value
(0.1, a and b; the vertical lines signify the base-case
value of ks, 1 h
1) or 10-fold lower (c and d). Fibroblast
penetration depth (determined as in Fig. 4 d) and
population size (
R l
0
vdx) were assessed at t ¼ 10 days
(a and c). The peak values in chemotactic signaling, Dm,
at the leading ﬁbroblast front and clot-dermis interface
at t ¼ 7 days are shown for the same parameter values
(b and d). The asterisks signify that the peak at the clot-
dermis interface is progressively moved rearward into the
dermis as ks gets large.
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v˜t ¼ Dvv˜xx1 k9v˜ð1 v˜nÞ;
v˜ ¼ v=vmax; k9 ¼ mm=ðg1 1Þ  kd:
(15)
In this case, it is well known that the cell density proﬁle will
assume a constant shape that propagates at a velocity of
2 Dvk9
 1=2
, in close agreement with the ﬁbroblast invasion
rate reached at high ks (assessed as in Fig. 4 d; results not
shown).
Of the two peaks in chemotactic signaling, Dm, the one
formed at the leading ﬁbroblast front drives invasion of the
ﬁbroblast population, whereas the other at the clot-dermis
interface serves a different, potentially important role:
preventing the ﬁbroblast proﬁle from dispersing back into
the dermis. Fibroblast invasiveness, as judged by penetration
depth and population size in the clot, therefore correlates
well with the Dm peak at the ﬁbroblast front and not with the
peak at the dermal interface as ks is varied (Fig. 5 b). With
either very low or very high ks, there is no discernible Dm
peak at the leading front.
As one might predict, the robustness of ﬁbroblast inva-
siveness as a function of PDGF secretion rate is enhanced
when the threshold for ﬁbroblast proliferation signaling is
lowered (Fig. 5, c and d). With a 10-fold reduction in the value
of g (Eq. 9), the peak in ﬁbroblast penetration depth is broad-
ened modestly, but it is the width of the ﬁbroblast population
size peak that more signiﬁcantly reﬂects the support of
ﬁbroblast proliferation at lower values of ks (compare Fig. 5, a
and c). As reasoned from the analysis presented in Fig. 3, the
reduction in g tends to increase the steady cell density vy and
reduce the minimum PDGF concentration needed for cell
stasis in the clot, ucrit; both effects contribute to enhance the
PDGF gradient steepness and thus chemotactic signaling at
the leading ﬁbroblast front, particularly in the low ks regime
(compare Fig. 5, b and d).
Large PDGF gradients promote ﬁbroblast invasion
but can also suppress the invasion rate
The other parameters that directly affect the PDGF proﬁle are
Du, ku, and kv, which were shifted from their base values by
one log in each direction to assess their impact on ﬁbroblast
invasiveness (Fig. 6 a) and the magnitudes of the two
chemotactic signaling peaks (Fig. 6 b). Reducing the value of
Du, the PDGF dispersion coefﬁcient, has little effect on the
leading Dm peak or ﬁbroblast penetration depth; the base Du
value is already sufﬁciently low, such that the steepness of
the PDGF gradient at the leading ﬁbroblast front mirrors that
of the ﬁbroblast density proﬁle (the Dm peak at the dermal
interface is sharpened considerably, however). In contrast, a
10-fold increase in Du is sufﬁcient to smear out the PDGF
concentration proﬁle and modestly reduce ﬁbroblast invasive-
ness. The effects of changes in the value of kv, the receptor-
mediated PDGF consumption rate constant, are similarly
predictable. Reducing the kv value by 10-fold leaves the
PDGF concentration proﬁle in the saturated regime, ablating
the leading Dm peak and reducing invasiveness, whereas an
increase in kv yields offsetting effects on the PDGF gradient;
Du is widened (by reducing uy, such that uy  ucrit, and
leaving umax unchanged), but at the expense of the cell density
that can be supported. Finally, shifting the value of ku, the rate
FIGURE 6 Sensitivity of ﬁbroblast invasiveness to
other PDGF rate constant values. Calculations were
performed as in Fig. 5 after adjustments to rate
constants in the PDGF balance, Eq. 7. See accom-
panying descriptions in the text. (a) Fibroblast
penetration depth and population size at t ¼ 10
days, normalized by the base-case values, after a 10-
fold reduction or increase in the indicated parameter
values. (b) Peak values in chemotactic signaling, Dm,
at the leading ﬁbroblast front and clot-dermis inter-
face at t ¼ 7 days were determined for the same
parameter values as in a. (c and d) Fibroblast density
and PDGF concentration proﬁles at t¼ 7 days for the
case of a 10-fold reduction in ku (c) or 10-fold
increases in both ks and kv (d); these parameter shifts
yield the same umax and nearly identical u
y values.
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constant characterizing background PDGF degradation,
yielded the most surprising results. Increasing its value by
10-fold inhibits invasiveness, which is easy enough to explain
based on a correspondingly lower umax, but decreasing its
value also results in reduced ﬁbroblast penetration. This was
contrary to expectation, because decreasing ku has little effect
on the PDGF concentration trailing the invading ﬁbroblast
front, uy (Fig. 3), while umax and thus Du are increased;
indeed, a higher Dm value is observed at the leading front.
How is the correlation between chemotactic signaling and
invasiveness broken? The decrease in ku affects the cell
density proﬁle dramatically, with a large spike in cell density
at the leading front (Fig. 6 c), and random migration of this
peak rearward proved to be the mitigating factor with respect
to the overall speciﬁc cell ﬂux Jv=v. This is forced in the
model by the saturation of receptor activation and thus the
rate of ﬁbroblast-mediated PDGF consumption at high
PDGF concentrations, which limits the ﬁbroblasts’ ability
to maintain the extremely sharp PDGF gradient as they
move. The analysis in Fig. 3 indicated that a similar PDGF
concentration proﬁle is achieved by increasing both ks and kv
by 10-fold. In this case, the leading ﬁbroblast density peak is
less pronounced and shows improved invasiveness, as the
larger value of kv better equips the cells for maintenance of
the large PDGF gradient (Fig. 6 d). Still, the enhancement in
penetration depth, 13% greater than the base case, was deemed
modest relative to the near twofold increase in chemotactic
signaling at the leading front (results not shown).
To further test the limitations on ﬁbroblast invasion rate,
the maximum chemotactic cell speed (Stax) was varied,
applying a different form of pressure on the cells to move
faster (Fig. 7). Here, the problem of balancing PDGF
consumption and ﬁbroblast invasion rates is solved by
broadening the ﬁbroblast density and PDGF concentration
proﬁles as Stax is increased, yielding a reduction in the
leading Dm peak value. As one might predict, the penetration
depth increases linearly with the product of Dm(Stax) (results
not shown).
DISCUSSION
The impetus of this work was not to provide accurate
estimates of ﬁbroblast density proﬁles or invasion rates
during wound healing, as it is fully acknowledged that the
PDGF-centric model presented here is a gross simpliﬁcation
of the actual ﬁbroblast response. Certainly the role of the
ECM, coupled with ﬁbroblast-mediated ECM alignment
and remodeling as considered in other modeling efforts
(39,40,47), is at best macroscopically lumped in the cell
migration and proliferation parameters, as are the effects of
the many other molecular and physical factors at play.
Rather, the goal was to explain the robustness of ﬁbroblast
invasiveness over relatively large length scales, across which
the PDGF concentration proﬁle might span several logs,
given the characterized sensitivity of PDGF gradient sens-
ing. In this sense, the major conclusions are expected to be
sufﬁciently general.
Model analysis suggests that a constant PDGF gradient,
suitable for stimulating ﬁbroblast chemotaxis, can be main-
tained through PDGF receptor activation-dependent consump-
tion of PDGF. The model is based on receptor-mediated
endocytosis and intracellular proteolysis of PDGF, which is
estimated to be signiﬁcant based on the density of cells in
tissue and the low concentrations at which growth factors are
effective. In principle, the cells might also utilize a pathway
linking receptor-mediated signaling to secretion or activation
of an extracellular protease, as considered in models of ECM-
driven haptotaxis (38,44,48). Thus, the PDGF gradient seen
by the leading cohort of invading ﬁbroblasts spans concen-
trations deﬁned by the presence versus absence of cells, and
near-optimal ﬁbroblast invasion is stimulated across a reason-
ably broad range of PDGF secretion rates. Reconciliation of
the trade-offs presented by the rates of cell proliferation,
receptor-mediated PDGF consumption, and cell chemotaxis
ultimately deﬁnes and in some cases limits ﬁbroblast in-
vasiveness.
Given that receptor-mediated consumption of PDGF is
cell density-dependent, the sensitivity of the ﬁbroblast prolif-
eration term to PDGF concentration turns out to be an important
consideration for chemotaxis (as explored in Figs. 3 and 5).
By reducing the saturation constant g, proliferation in the
clot becomes insensitive to PDGF, effectively decoupling
proliferation and chemotaxis and allowing greater ﬂexibility
in how the ﬁbroblast population responds. A priori, one can
expect then that adding to the model factors that inﬂuence
ﬁbroblast proliferation but not chemotaxis (e.g., insulin-like
FIGURE 7 Variation of ﬁbroblast invasiveness with maximum chemo-
tactic cell speed. The peak value in chemotactic signaling (Dm) at the leading
ﬁbroblast front is a decreasing function of the maximum chemotactic cell
speed, Stax. The penetration depth at t¼ 10 days, evaluated as in Fig. 5, a and
c, increases linearly with the change in the product of Dm(Stax). Above the
base-case Stax value of 0.1 mm/h, the ﬁbroblasts reach the exterior boundary
of the 3 mm clot by 10 days, and so the comparable penetration depth was
estimated by extrapolation of the constant propagation velocity regime (values
denoted by asterisks).
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growth factor-1, certain components of the clot ECM) will
produce the same effect.
Aside from adding more spatiotemporally varying regula-
tory factors, how might this invasion model be reﬁned? As
implemented in certain studies (40,49–53), a hybrid model
wherein discrete ﬁbroblasts respond stochastically to contin-
uous external variables may be constructed. Heterogeneity
among individual cells, with respect to expression levels of
receptors, PI 3-kinase, and any other cell-associated mole-
cules, for example, may then be considered. In the context
of the model, such heterogeneity would affect each cell’s
contribution to PDGF consumption as well as its responsive-
ness to the gradient, perhaps leading to invasion of a select
ﬁbroblast subpopulation. From our perspective, a more
signiﬁcant reﬁnement would be to replace the hypothetical,
phenomenological model of cell movement control (Eqs.
10 and 11) with a more mechanistic description. Clearly, the
difﬁcult task of relating, through quantitative experiment and
analysis, 1), signal transduction through PI 3-kinase and/or
other pathways, 2), cell polarity and cytoskeletal dynamics,
and 3), cell migration characteristics needs to be undertaken if
we wish to better understand chemotactic invasion processes.
APPENDIX A: PDGF RECEPTOR ACTIVATION AT
QUASI-STEADY STATE
A kinetic model is presented here, starting from our previous PDGF receptor
dimerization mechanism and model (28), with the addition of slower
processes such as receptor synthesis, basal receptor turnover, and intracel-
lular receptor trafﬁcking. Treatment of those additional effects follows the
recent model of human growth hormone receptor activation (54). It is
subsequently shown how this reasonably detailed model may be approx-
imated by the scaled, steady-state receptor activation function (Eq. 2), with
no additional parameters. The kinetic balances are:
dC1
dt
¼ kf ½LR1 kxC2  ðkr1 ktÞC1  2kx C21; (16)
dC2
dt
¼ kxC21  ðkx1 keÞC2; (17)
dR
dt
¼ Vs1 krC11 kxC2  ðkf ½L1 ktÞR1 krec Ri; (18)
dRi
dt
¼ ktðR1C1Þ1 2keð1 fDÞC2  ðkrec1 kdegÞRi; (19)
C1ð0Þ ¼ C2ð0Þ ¼ 0; Rð0Þ ¼ R0 ¼ Vs
kt
11
krec
kdeg
 
;
Rið0Þ ¼ ktR0=ðkrec1 kdegÞ:
(20)
C1, C2, R, and Ri are the numbers of 1:1 ligand-receptor complexes, active
PDGF receptor dimers, empty PDGF receptors, and internalized receptors
available for recycling, respectively. It is assumed that a constant fraction fD
of receptors internalized as dimers are marked for degradation and thus not
included in Ri (one might ﬁnd it reasonable to further assume fD ¼ 1, but I
wish to derive a more general case). [L] is the extracellular concentration of
PDGF, assumed to be constant or changing slowly, and Vs is the rate of new
PDGF receptor synthesis. R0 is deﬁned as the number of PDGF receptors on
the cell surface in the absence of PDGF. Other rate constant deﬁnitions are
given in the sources cited above.
Combining Eqs. 16–20 reveals the following steady-state balance on
receptor species:
R0 ¼ R1C11 2ke
kt
11
krecfD
kdeg
 
C2: (21)
Equation 17 gives the relationship between C2 and C1 at steady state:
C2 ¼ KXC21; KX ¼ kx=ðkx1 keÞ: (22)
Together with Eq. 16 and after some simpliﬁcation, one obtains the dimer
fraction, 2C2/R0, at steady state:
2C2
R0
¼ KXR0 11 4kxu1u2  ð11 8kxu1u2Þ
1=2
4k
2
xu
2
2
" #
;
u1 ¼
kf ½L
kr1 kt1 kf ½L; u2 ¼ u11bð1 u1Þ;
kx ¼ ke
kt
11
krecfD
kdeg
 
KXR0;
b ¼ 11 kx=2ke
11 kr=ktð Þ 11 krecfD=kdeg
 : (23)
Normalizing 2C2 by its saturation value, 2C2,max (u1 ¼ u2 ¼ 1), gives the
fractional receptor activation, r:
r ¼ C2
C2;max
¼ 11 4kxu1u2  ð11 8kxu1u2Þ
1=2
u22 11 4kx  ð11 8kxÞ1=2
h i : (24)
In dimensionless form, with [L] scaled by (kr 1 kt)/kf  KD,L, Eq. 24
contains only two adjustable parameters, kx and b, yet it was found that one
can simplify this expression even further. Order-of-magnitude estimates,
based on parameters reported previously (28) and analysis presented in
Appendix C, place kx;100 and b no greater than;0.01. It is readily shown
that Eq. 24, with b ¼ 0, is equivalent to the solution obtained with the
a priori assumption of pseudo-equilibrium for 1:1 complex formation
(C1¼ [L]R/KD,L), as justiﬁed previously (28). With b 1, it was found that
Eq. 24 is closely approximated by Eq. 2, with u deﬁned as [L]/L*, where
L* is whichever value of [L] gives r ¼ 1/3.
APPENDIX B: DERIVATION OF AVERAGE
RECEPTOR ACTIVATION AND SECOND
MESSENGER METRICS
Expressions are derived here for Æræ, the average receptor activation level,
=Æmæ, the gradient of average 39 PI level across various cells, and Dm, the
asymmetry in 39 PI density within a single cell (chemotactic driving force)
(Eq. 10). Given a linear PDGF gradient on the length scale of a cell, u(j) (Eq.
1), and the local receptor activation function r(u) from Eq. 2, the mean
receptor activation is as follows:
Æræ ¼
Z 1
0
rdj ¼ 1
ej=uj
Z uð1Þ
uð0Þ
z
2
dz
11 z1 z2
¼ 1 1
3
1=2ej=ujtan
1 3
1=2ej=uj
21 u1 2uð1Þuð0Þ
" #
 1
2ej=ujln
11 uð1Þ1 u2ð1Þ
11 uð0Þ1 u2ð0Þ
 
: (25)
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Performing a series expansion, with appropriate simpliﬁcation,
Æræ  u
2
11 u1 u2
1
ðej=ujÞ2ð1 3u2  u3Þ
12ð11 u1 u2Þ3 : (26)
Analysis of Eqs. 25 and 26 reveals that the second term in Eq. 26 may safely
be neglected, and so it is reasonable to further approximate that
Æræ  rðuÞ: (27)
The distinction between u and u may now be dropped. With Eq. 27, one
applies the chain rule to obtain
=Æmæ ¼
"
að1 m0Þð1 ÆeæÞ
k1 11aÆræ 2Æeæ
#
ð2u1 u2Þ=u
ð11 u1 u2Þ2: (28)
Under the same conditions for which Eq. 25 simpliﬁes to Eq. 27,
Dm ¼ e
2
"
að1 ÆeæÞ
k1 1 Æeæ
#
ð2u1 u2Þ=u
ð11 u1 u2Þ2: (29)
Or, in terms of the relative gradient (percent difference) across the cell,
d ¼ ej= lnuj,
jDmj ¼ ð21 uÞÆeæ
2ð11 u1 u2Þ d: (30)
Note that Eqs. 29 and 30 are equivalent to the result that one obtains
assuming a linear messenger proﬁle inside the cell (i.e., Dm [m(1) – m(0)]/
2 ¼ [e(1) – e(0)]/2).
APPENDIX C: PARAMETER ESTIMATES
PDGF diffusion
The diffusion coefﬁcient of PDGF (24 kDa) in solution is ;106 cm2/s
(;0.3 mm2/h), but proteins are far less mobile in tissues (55,56). The base-
case value ofDu used in the model (0.01 mm
2/h) is;30 times lower than for
diffusion in aqueous solution.
Fibroblast-mediated PDGF depletion
To derive the magnitude of the rate constant kv, one needs to estimate the
PDGF concentration, ﬁbroblast density, and receptor activation level that
give, in dimensionless terms, u ¼ 1, v ¼ 1, and r ¼ 1, respectively. The ﬁrst
of these is derived from the steady-state receptor activation model (Eq. 24,
with b 0). From our previous analysis of PDGF receptor activation in NIH
3T3 ﬁbroblasts, the parameter grouping keKXR0 is estimated as 0.21
min1, andKD,L 1.5 nM (28). The grouping R0/Vs is the characteristic time
required to synthesize all of the cell’s initial surface receptors. A reasonable
range, based on EGF receptor synthesis in ﬁbroblasts, is R0/Vs  300–1000
min (57,58). Together with fD  1, it is estimated that kx  60–200. Noting
that r ¼ 1/3 when u ¼ [L]/L*  1, it is estimated that L* ; 0.1–0.2 nM. A
modest ﬁbroblast density in dermal tissue is taken as;105 cells/ml (,1 vol
%). Considering the inﬂuence of receptor downregulation by ligand-induced
endocytosis, perhaps balanced by induction of PDGF receptor synthesis at
the level of transcription (28,59–61), the maximum number of activated
PDGF receptors at steady state is considered to be in the range of 104–105/
cell. Together with an endocytic rate constant for activated PDGF receptors
0.2 min1 (28) and the range of L* estimated above, one obtains a range of
0.1–2 h1 for kv, from which a value of 1 h
1 was deemed reasonable. It
should be noted that another model of dermal wound healing assumed a
lower ﬁbroblast density in the dermis (;104/ml) but in essence the same
contact-inhibited density as inferred here (;106/ml) (39).
Cell migration parameters
The characteristic value of the cell dispersion coefﬁcient, Dv, (3 3 10
4
mm2/h¼ 5 mm2/min) is based on quantitative cell tracking measurements of
ﬁbroblasts migrating on ECM in two and three dimensions (45,62–64).
Maximum ﬁbroblast speeds in those experiments, under random migration
conditions, is ;0.5 mm/min (0.03 mm/h). The base-case estimate of the
maximum chemotactic cell speed, Stax, is conservatively taken as ;3 times
this value (0.1 mm/h) to reﬂect enhancement in net cell translocation rate
when membrane protrusion and other motility processes are spatially asym-
metric.
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